Hand drug pharmaceutical health Colin Campbell/Flickr




实现这一点的一个重要途径是开发新药。在一篇即将发表的文章中,抗耐药性评估(Review on Antimicrobial Resistance)估计,实现新抗生素上市并改善它们的管理需要耗资大约250亿美元——一笔巨款,但和问题得不到解决所引起的社会成本相比只是九牛一毛。而这也是世界最大的两家制药公司今年用于回购本公司股票的金额。

To continue reading, please log in or enter your email address.

To access our archive, please log in or register now and read two articles from our archive every month for free. For unlimited access to our archive, as well as to the unrivaled analysis of PS On Point, subscribe now.


By proceeding, you agree to our Terms of Service and Privacy Policy, which describes the personal data we collect and how we use it.

Log in


Cookies and Privacy

We use cookies to improve your experience on our website. To find out more, read our updated cookie policy and privacy policy.